Literature DB >> 23136603

Combined influence of adjuvant therapy and interval after surgery on peripheral CD4(+) T lymphocytes in patients with esophageal squamous cell carcinoma.

Yang Ling1, Lieying Fan, Chunlei Dong, Jing Zhu, Yongping Liu, Yan Ni, Changtai Zhu, Changsong Zhang.   

Abstract

The aim of this study was to investigate possible differences in cellular immunity between chemo- and/or radiotherapy groups during a long interval after surgery in esophageal squamous cell carcinoma (ESCC) patients. Cellular immunity was assessed as peripheral lymphocyte subsets in response to chemotherapy (CT), radiotherapy (RT) and CT+RT by flow cytometric analysis. There were 139 blood samples obtained at different time points relative to surgery from 73 patients with ESCC. The changes in the absolute and relative proportions of lymphocyte phenotypes were significant among the adjuvant therapy groups. There were significant differences in the absolute counts of CD4(+) and CD8(+) T cells among the interval groups, and a lower CD4/CD8 ratio was found in patients following a prolonged interval. RT alone had a profound effect on the absolute counts of CD3(+), CD4(+) and CD8(+) T cells compared with the other groups. CD4(+) T cells exhibited a decreasing trend during a long interval, leading to a prolonged T-cell imbalance after surgery. Univariate analysis revealed that the interaction of the type of adjuvant therapy and the interval after surgery was correlated only with the percentage of CD4(+) T cells. The percentage of CD4(+) T cells can be used as an indicator of the cellular immunity after surgery in ESCC patients. However, natural killer cells consistently remained suppressed in ESCC patients following adjuvant therapy after surgery. These findings confirm an interaction between adjuvant therapy and the interval after surgery on peripheral CD4(+) T cells, and implies that adjuvant therapy may have selective influence on the cellular immunity of ESCC patients after surgery.

Entities:  

Year:  2010        PMID: 23136603      PMCID: PMC3490396          DOI: 10.3892/etm_00000020

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  27 in total

Review 1.  CD4+ T cell matters in tumor immunity.

Authors:  Markwin P Velders; Mary A Markiewicz; Gretchen L Eiben; W Martin Kast
Journal:  Int Rev Immunol       Date:  2003 Mar-Apr       Impact factor: 5.311

Review 2.  Chemoradiation in the management of esophageal cancer.

Authors:  Lawrence Kleinberg; Arlene A Forastiere
Journal:  J Clin Oncol       Date:  2007-09-10       Impact factor: 44.544

3.  Effects of chemoradiation on tumor-host interactions: the immunologic side.

Authors:  Silvia C Formenti; Sandra Demaria
Journal:  J Clin Oncol       Date:  2008-03-20       Impact factor: 44.544

4.  Constraints on CD4 recovery postchemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells.

Authors:  F T Hakim; R Cepeda; S Kaimei; C L Mackall; N McAtee; J Zujewski; K Cowan; R E Gress
Journal:  Blood       Date:  1997-11-01       Impact factor: 22.113

Review 5.  Tumor antigen-specific T helper cells in cancer immunity and immunotherapy.

Authors:  K L Knutson; M L Disis
Journal:  Cancer Immunol Immunother       Date:  2005-01-27       Impact factor: 6.968

6.  Expression of a tolerizing tumor antigen in peripheral tissue does not preclude recovery of high-affinity CD8+ T cells or CTL immunotherapy of tumors expressing the antigen.

Authors:  C Ohlén; M Kalos; D J Hong; A C Shur; P D Greenberg
Journal:  J Immunol       Date:  2001-02-15       Impact factor: 5.422

7.  Influence of multimodality therapy on the cellular immunity of patients with esophageal cancer.

Authors:  K Mafune; Y Tanaka
Journal:  Ann Surg Oncol       Date:  2000-09       Impact factor: 5.344

Review 8.  Protein alterations in ESCC and clinical implications: a review.

Authors:  D-C Lin; X-L Du; M-R Wang
Journal:  Dis Esophagus       Date:  2008-06-17       Impact factor: 3.429

9.  Adaptive immunity maintains occult cancer in an equilibrium state.

Authors:  Catherine M Koebel; William Vermi; Jeremy B Swann; Nadeen Zerafa; Scott J Rodig; Lloyd J Old; Mark J Smyth; Robert D Schreiber
Journal:  Nature       Date:  2007-11-18       Impact factor: 49.962

10.  Differential responses of cellular immunity in patients undergoing neoadjuvant therapy followed by surgery for carcinoma of the oesophagus.

Authors:  Marinke Westerterp; Marja A Boermeester; Jikke M T Omloo; Maarten C C M Hulshof; Walter L Vervenne; Rene Lutter; Theo A Out; J Jan B van Lanschot
Journal:  Cancer Immunol Immunother       Date:  2008-04-09       Impact factor: 6.968

View more
  1 in total

Review 1.  Neoadjuvant therapy for advanced esophageal cancer: the impact on surgical management.

Authors:  Masahiko Ikebe; Masaru Morita; Manabu Yamamoto; Yasushi Toh
Journal:  Gen Thorac Cardiovasc Surg       Date:  2016-05-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.